H.C. Wainwright analyst Robert Burns raised the firm’s price target on Adicet Bio (ACET) to $9 from $4 and keeps a Buy rating on the shares. The firm views ADI-001’s profile as “extremely attractive” in both lupus nephritis and systemic lupus erythematosus.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Adicet Bio Inc. Reports Q3 2025 Financial Results
- Adicet Bio reports Q3 EPS , consensus (32c)
- Adicet Bio reports Q3 EPS (29c), consensus (32c)
- Adicet Bio doses first patient in ADI-001 trial
- Adicet Bio’s Promising Off-the-Shelf Cell Therapy Garners Buy Rating Due to Positive Clinical Outcomes and Strong Market Position